Cancer Research SABCS Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shao, R.
Right arrow Articles by Hung, M.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shao, R.
Right arrow Articles by Hung, M.-C.
[Cancer Research 60, 3123-3126, June 15, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Inhibition of Angiogenesis and Induction of Apoptosis Are Involved in E1A-mediated Bystander Effect and Tumor Suppression1

Ruping Shao, Weiya Xia and Mien-Chie Hung2

Department of Molecular and Cellular Oncology, Breast Cancer Basic Research Program, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 
Adenovirus type 5 E1A has been implicated in mediation of tumor suppression. Preclinical gene therapy studies have additionally shown that complete growth suppression can be achieved by incomplete transfer of E1A into tumors, suggesting that a bystander effect may also be associated with E1A. In this study, we investigated the E1A-mediated bystander effect and the mechanisms that may be associated with it. By s.c. inoculating nude mice with a mixture of E1A transfectants and parental cells, we found that the E1A transfectants exhibited a bystander effect on inhibition of tumor growth. We further showed that E1A mediated suppression of angiogenesis and induction of apoptosis in the tumors, likely contributing to the bystander effect. In addition, coculture of E1A transfectants and parental cells in a Transwell unit led to growth retardation and apoptosis mediated by the supernatant in the parental cells, indicating that a secreted factor may also contribute to the bystander effect. Taken together, our results suggested that E1A mediates a bystander effect on tumor suppression by inhibiting angiogenesis and inducing apoptosis.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results and Discussion
 REFERENCES
 
The bystander effect was originally identified through a study in which cancer cells modified by the herpes simplex virus thymidine kinase gene caused the death of nearby unmodified cancer cells after administration of the drug ganciclovir (1) . In this case, gap junctional intercellular communication was the mechanism responsible for bystander killing (2) . However, recent studies have shown that tumor cells transfected with genes such as IFN-ß, interleukin 4, and p53 exhibit bystander effects with alternative mechanisms, including enhancement of the immune response and suppression of angiogenesis (3, 4, 5) , which has been shown to play an important role in tumor growth and metastasis (6 , 7) .

Ad53 E1A has recently been demonstrated to exhibit antioncogenic activity by suppressing transformation, metastasis, and tumorigenicity via multiple mechanisms (8, 9, 10, 11, 12, 13) . The molecular mechanisms that may be associated with this antioncogenic activity include down-regulation of transforming and metastasis genes such as HER-2/neu, Axl, stromelysin, plasminogen activator, urokinase, and type 4 collagenase (8 , 14) .

E1A has also been shown to increase the susceptibility of cells to tumor necrosis factor and {gamma}-radiation (15 , 16) , enhance their susceptibility to host cellular immune responses, and sensitize them to apoptosis induced by various stimuli such as high cell density. E1A can also induce apoptosis in a cell-free system and in both p53-dependent and p53-independent manners (17, 18, 19) . Moreover, local and systemic liposome- and adenovirus-mediated delivery of E1A results in significant tumor suppression in cell lines and mouse models (10 , 11) . Current methodology for E1A transfection is not 100% successful; hence, we raised the question as to whether E1A-mediated tumor suppression might be due in part to a bystander effect. To test this possibility, we investigated the bystander effect on tumor development in nude mice inoculated with Ad5 E1A transfectant cells.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results and Discussion
 REFERENCES
 
Cell Lines and Culture.
Cell lines used were parental human ovarian cancer line SKOV3.ip1, stable Ad5 E1A transfectants of SKOV3.ip1 (ip1-E1A2), E1A frameshift mutant transfectants of SKOV3.ip1 (ip1-Efs), and the human breast cancer cell line MDA-MB-435 (American Type Culture Collection, Manassas, VA). All cultures were established and grown as described by Shao et al. (16) .

Tumor Cell Inoculation.
Female 4–5-week-old nude mice were purchased from Harlan Bioproducts for Science, Inc. (Indianapolis, IN) and maintained in the animal facility of The University of Texas M. D. Anderson Cancer Center. Mice were divided into six experimental groups containing five mice each. One group was inoculated s.c. with a cell mixture of 2 x 106 ip1-E1A2 cells and an equal amount of parental SKOV3.ip1 cells to induce tumor. A second group was inoculated with 1 x 106 ip1-E1A2 cells and an equal amount of MDA-MB-435 cells. The remaining groups were inoculated with equal numbers of SKOV3.ip1, MDA-MB-435, or ip1-E1A2 cells alone. Cells were injected into the flanks of the mice, and each mouse was inoculated with tumors at two sites. Tumor volumes were measured and recorded once a week for 4–7 weeks. Each experiment was repeated at least one time.

Immunohistochemistry.
Histological sections of ip1-E1A2/SKOV3.ip1-, ip1-E1A2-, and SKOV3.ip1-induced tumors were taken, fixed with formalin, and embedded in paraffin. The sections were incubated with rabbit antibody against factor VIII (1:200; Dako Corp., Carpinteria, CA), followed by incubation with biotinylated goat antirabbit IgG (1:200; Vector Laboratories, Inc., Burlingame, CA). Sections were then incubated with an avidin-biotin complex-horseradish peroxidase conjugate and developed using aminoethylcarbazole chromogen (Sigma, St. Louis, MO) as a substrate. Positive signals were visualized by light microscopy at high power (x400), and the number of microvessels was counted in six x200 fields for each tumor section.

Tumor Apoptosis Assay.
The sections from ip1-E1A2/SKOV3.ip1-, ip1-E1A2-, and SKOV3.ip1-induced tumors were taken and analyzed for apoptosis by TUNEL assay as described by Shao et al. (15) .

[3H]Thymidine Incorporation.
Cells were cocultured in a 24-well Transwell unit containing an upper and a lower chamber (Costar Corporate, Cambridge, MA). The chambers were separated by a membrane that allowed the medium, but not the cells, to penetrate freely. The upper chamber was filled with 2 x 104 ip1-E1A2 cells or ip1-Efs, SKOV3.ip1, or MDA-MB-435 control cells in 100 µl of medium. The lower chamber was filled with 1.5 x 104 SKOV3.ip1 or MDA-MB-435 cells in 600 µl of medium. The supernatant from the upper chamber, which was replaced with 100 µl of fresh medium, was filtered and used to replace 100 µl of the medium from the lower chamber each day. After 72 h of culture, 3 µCi of [3H]thymidine in 20 µl of medium were added into the lower chamber, and incubation was continued for another 16 h. Thymidine incorporation was determined with a scintillation counter.

In Vitro Apoptosis Assay.
To analyze apoptosis in bystander cells induced by E1A transfectants in culture, we cultured 3 x 105 ip1-E1A2, ip1-Efs, or SKOV3.ip1 cells in the upper chamber and 1.5 x 104 SKOV3.ip1 cells in the lower chamber of the Transwell unit under serum starvation conditions. After 96 h of culture, cells were trypsinized and harvested for TUNEL assay as described by Shao et al. (15) .


   Results and Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
REFERENCES
 
E1A has exhibited multiple tumor-suppressive properties (8) . To test whether E1A could mediate a bystander effect on tumor development, a human ovarian cancer cell line derivative (SKOV3.ip1), the wild-type Ad5 E1A stable transfectant of SKOV3.ip1 (ip1-E1A2), the human breast cancer cell line MDA-MB-435, and ip1-E1A2/SKOV3.ip1 and ip1-E1A2/MDA-MB-435 mixtures were used to inject tumors ectopically in nude mice. Tumors induced by the cell mixtures or ip1-E1A2 cells alone grew more slowly than those induced by either SKOV3.ip1 or MDA-MB-435 cells alone (Fig. 1, A and BCitation ). These results, consistent with previous results from our laboratory (8 , 10 , 11) , indicated that E1A mediates tumor suppression. In addition, data showed that ip1-E1A2 cells mediated a bystander effect by suppressing tumor growth induced by the SKOV.3 ip1 or MDA-MB-435 cells.



View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Bystander effect and tumor suppression mediated by ip1-E1A2 cells. Nude mice (n = 5) were injected with various cells and cell mixtures to induce tumors at two sites in each mouse, A, SKOV3.ip1, ip1-E1A2 + SKOV3.ip1, or ip1-E1A2 cells; B, MDA-MB-435 (435); ip1-E1A2 + MDA-MB-435 (ip1-E1A2+435), or ip1-E1A2 cells. Tumor volumes were measured and recorded once a week for 4 (A) and 7 weeks (B). Each point on the figure represents the mean volume of 10 tumors.

 
Recent studies have shown that angiogenesis is one of the important factors affecting tumor growth. Factor VIII, which presents on the blood vessel endothelial cells, has been used as a marker for angiogenesis (6) . To examine whether E1A-mediated tumor suppression involves a change in angiogenesis and whether the change is involved in the bystander effect, we performed immunohistochemical staining for factor VIII in tumor tissue. Discrete microvessel counts and neovascularization in tumors induced by ip1-E1A2/SKOV3.ip1 cell mixtures (Fig. 2ACitation ) and ip1-E1A2 cells alone (Fig. 2BCitation ) were dramatically lower than those in tumors induced by SKOV3.ip1 cells alone (Fig. 2CCitation ). These results suggest that E1A mediates the antiangiogenic suppression process of blood vessel formation and that this action is involved in the bystander effect.



View larger version (90K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Inhibition of angiogenesis mediated by ip1-E1A2 cells. Histological sections from tumors induced by various cell lines were embedded in paraffin and stained for factor VIII. A, SKOV3.ip1 plus ip1-E1A2 cells; B, ip1-E1A2 cells; C, SKOV3.ip1 cells. SDs were calculated after viewing six independent x200 fields.

 
In addition to angiogenesis, apoptosis has been implicated in cancer pathogenesis and treatment (20) and as a mechanism for bystander cell death (2) . E1A has been shown to induce apoptosis in vitro; therefore, to determine whether E1A could mediate apoptotic changes in vivo, we analyzed tumor sections by TUNEL assay. Tumors induced by ip1-E1A2/SKOV3.ip1 cell mixtures and by ip1-E1A2 cells alone exhibited apoptosis in 7% and 9% of the cells examined, respectively (Fig. 3, A and BCitation ), whereas tumors induced by SKOV3.ip1 cells showed apoptosis in <1% of cells examined (Fig. 3CCitation ). These results indicate that E1A mediates apoptosis not only in tumors induced by the E1A transfectants but also in tumors induced by the cell mixtures.



View larger version (62K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Apoptosis in tumors mediated by ip1-E1A2 cells. Sections were taken from tumors induced by various cells and cell mixtures. A, ip1-E1A2 plus SKOV3.ip1; B, ip1-E1A2 cells; C, SKOV3.ip1 cells. Sections were analyzed for apoptosis by TUNEL assay. Arrows point to representative apoptotic cells. SDs were derived from two separate counts of apoptotic cells.

 
It has been shown that cytokines or other factors secreted by transfected cells can induce bystander effects (3, 4, 5) . To further investigate whether our bystander effect was mediated by a factor secreted from ip1-E1A2 cells, we cocultured SKOV3.ip1 or MDA-MB-435 cells with ip1-E1A2 or control ip1-Efs cells in a Transwell unit. Their mitogenic activity was measured by [3H]thymidine incorporation. The mitogenic activity of SKOV3.ip1 or MDA-MB-435 cells cocultured with ip1-E1A2 cells was lower than that of SKOV3.ip1 or MDA-MB-435 cells cocultured with ip1-Efs cells, which do not produce functional E1A proteins (Fig. 4, A and BCitation ). This indicated that ip1-E1A2 cells could mediate inhibition of mitogenic activity of SKOV3.ip1 and MDA-MB-435 cells and that the effect was caused by a secretable factor(s) present in the ip1-E1A2 cell supernatant. To further examine whether ip1-E1A2 cells could secrete this factor(s) to induce apoptosis in vitro, we cultured SKOV3.ip1 cells alone or with either ip1-E1A2 or control ip1-Efs cells in Transwell units under serum starvation conditions to induce apoptosis. Twenty percent of SKOV3.ip1 cells underwent apoptosis when cultured with ip1-E1A2 cells as compared with 5% and 3% of SKOV3.ip1 cells cultured with ip1-Efs cells or alone, respectively (Fig. 4CCitation ). These results indicate that cells transfected with E1A mediated a bystander effect by releasing a secretable factor to inhibit mitosis and enhance apoptosis through the culture supernatant under serum withdrawal conditions. Taken together, our results suggest that E1A-mediated inhibition of angiogenesis, induction of apoptosis, and suppression of mitosis may contribute to the bystander effect on E1A-mediated tumor suppression.



View larger version (64K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Inhibition of [3H]thymidine incorporation and enhancement of apoptosis mediated by ip1-E1A2 cells in vitro. Cells were cultured in the Transwell unit, [3H]thymidine was added to the lower chambers, and the radioactivity of harvested cells was determined by scintillation. A, SKOV3.ip1 cells in the lower chamber and ip1-E1A2, ip1-Efs, or control SKOV3.ip1 cells in the upper chamber. B, MDA-MB-435 (435) cells in the lower chamber and ip1-E1A2, ip1-Efs, or control MDA-MB-435 cells in the upper chamber. Additional cells were grown under serum stavation conditions, harvested after 96 h, and analyzed by TUNEL assay. C, SKOV3.ip1 cells in the lower chamber and ip1-E1A2, ip1-Efs, or control SKOV3.ip1 cells in the upper chamber. Bars, SDs determined from three independent experiments.

 


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by NIH Grants CA58880 and CA77858 and Ovarian Specialized Programs of Research Excellence Grant P50 CA83639 (to M-C. H.). Back

2 To whom requests for reprints should be addressed, at Department of Molecular and Cellular Oncology, Breast Cancer Basic Research Program, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 108, Houston, TX 77030. Phone: (713) 792-3630; Fax: (713) 794-0209. Back

3 The abbreviations used are: Ad5, adenovirus type 5; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling. Back

Received 1/28/00. Accepted 5/ 4/00.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 

  1. Culver K. W., Ram Z., Wallbridge S., Ishii H., Oldfield E. H., Blaese R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of exprimental brain tumors. Science (Washington DC), 256: 1550-1552, 1992.[Abstract/Free Full Text]
  2. Mesnil M., Piccoli C., Tiraby G., Willecke K., Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA, 93: 1831-1835, 1996.[Abstract/Free Full Text]
  3. Dong Z., Greene G., Pettaway C., Dinney C. P. N., Eue I., Lu W., Bucana C. D., Balbay M. D., Bielenberg D., Fidler I. J. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-ß. Cancer Res., 59: 872-879, 1999.[Abstract/Free Full Text]
  4. Wei M. X., Tamiya T., Hurford R. K., Jr., Boviatsis E. J., Tepper R. I., Chiocca E. A. Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. . Hum. Gene Ther., 6: 437-443, 1995.[Medline]
  5. Nishizaki M., Fujiwara T., Tanida T., Hizuta A., Nishimori H., Tokino T., Nakamura Y., Bouvet M., Roth J. A., Tanaka N. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin. Cancer Res., 5: 1015-1023, 1999.[Abstract/Free Full Text]
  6. Weidner N., Semple J. P., Welch W. R., Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.[Abstract]
  7. Bergers G., Javaherian K., Lo K. M., Folkman J., Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (Washington DC), 284: 808-812, 1999.[Abstract/Free Full Text]
  8. Yu D., Hung M. C. The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. Cancer Metastasis Rev., 17: 195-202, 1998.[Medline]
  9. Mymryk J. S. Tumour suppressive properties of the adenovirus 5 E1A oncogene. Oncogene, 13: 1581-1589, 1996.[Medline]
  10. Chang J. Y., Xia W., Shao R., Sorgi F., Hortobagyi G. N., Huang L., Hung M. C. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene, 14: 561-568, 1997.[Medline]
  11. Chang J. Y., Xia W., Shao R., Hung M. C. Inhibition of intratracheal lung cancer development by systemic delivery of E1A. Oncogene, 13: 1405-1412, 1996.[Medline]
  12. Schaeper U., Boyd J. M., Verma S., Uhlmann E., Subramanian T., Chinnadurai G. Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Proc. Natl. Acad. Sci. USA, 92: 10467-10471, 1995.[Abstract/Free Full Text]
  13. Frisch S. M., Dolter K. E. Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism. Cancer Res., 55: 5551-5555, 1995.[Abstract/Free Full Text]
  14. Lee W. P., Liao Y., Robinson D., Kung H. J., Liu E. T., Hung M. C. Axl-Gas6 interaction counteracts E1A-mediated cell growth suppression and proapoptotic activity. Mol. Cell. Biol., 19: 8075-8082, 1999.[Abstract/Free Full Text]
  15. Shao R., Hu M. C. T., Zhou B. P., Lin S. Y., Chiao P. J., von Lindern R. H., Spohn B., Hung M. C. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of I{kappa}B kinases and nuclear factor {kappa}B activities. J. Biol. Chem., 274: 21495-21498, 1999.[Abstract/Free Full Text]
  16. Shao R., Karunagaran D., Zhou B. P., Li K., Lo S. S., Deng J., Chiao P., Hung M. C. Inhibition of nuclear factor {kappa}B activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J. Biol. Chem., 272: 32739-32742, 1997.[Abstract/Free Full Text]
  17. Fearnhead H. O., McCurrach M. E., O’Neill J., Zhang K., Lowe S. W., Lazebnik Y. A. Oncogene-dependent apoptosis in extracts from drug-resistant cells. Genes Dev., 11: 1266-1276, 1997.[Abstract/Free Full Text]
  18. de Stanchina E., McCurrach M. E., Zindy F., Shieh S. Y., Ferbeyre G., Samuelson A. V., Prives C., Roussel M. F., Sherr C. J., Lowe S. W. E1A signaling to p53 involves the p19ARF tumor suppressor. Genes Dev., 12: 2434-2442, 1998.[Abstract/Free Full Text]
  19. Chiou S. K., White E. p300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis. J. Virol., 71: 3515-3525, 1997.[Abstract]
  20. Bruckheimer E. M., Gjertsen B. T., McDonnell T. J. Implications of cell death regulation in the pathogenesis and treatment of prostate cancer. Semin. Oncol., 26: 382-398, 1999.[Medline]



This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
X. Xie, J. L. Hsu, M.-G. Choi, W. Xia, H. Yamaguchi, C.-T. Chen, B. Q. Trinh, Z. Lu, N. T. Ueno, J. K. Wolf, et al.
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer
Mol. Cancer Ther., August 1, 2009; 8(8): 2375 - 2382.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Bartholomeusz, H. Itamochi, L. X.H. Yuan, F. J. Esteva, C. G. Wood, N. Terakawa, M.-C. Hung, and N. T. Ueno
Bcl-2 Antisense Oligonucleotide Overcomes Resistance to E1A Gene Therapy in a Low HER2-Expressing Ovarian Cancer Xenograft Model
Cancer Res., September 15, 2005; 65(18): 8406 - 8413.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
R. Shao, D.-F. Lee, Y. Wen, Y. Ding, W. Xia, B. Ping, H. Yagita, B. Spohn, and M.-C. Hung
E1A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis through Enhancement of Caspase Activation
Mol. Cancer Res., April 1, 2005; 3(4): 219 - 226.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. M. Frisch
E1A as a Tumor Suppressor Gene: Commentary re S. Madhusudan et al. A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene. Clin Cancer Res 2004;10:2905-2907.
Clin. Cancer Res., May 1, 2004; 10(9): 2905 - 2907.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Madhusudan, A. Tamir, N. Bates, E. Flanagan, M. E. Gore, D. P. J. Barton, P. Harper, M. Seckl, H. Thomas, N. R. Lemoine, et al.
A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene
Clin. Cancer Res., May 1, 2004; 10(9): 2986 - 2996.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Schaack, M. L. Bennett, J. D. Colbert, A. V. Torres, G. H. Clayton, D. Ornelles, and J. Moorhead
E1A and E1B proteins inhibit inflammation induced by adenovirus
PNAS, March 2, 2004; 101(9): 3124 - 3129.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Z. Zhou, R.-R. Zhou, H. Guan, C. D. Bucana, and E. S. Kleinerman
E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model
Mol. Cancer Ther., December 1, 2003; 2(12): 1313 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W.-P. Lee, D.-I. Tai, S.-L. Tsai, C.-T. Yeh, Y. Chao, S.-D. Lee, and M.-C. Hung
Adenovirus Type 5 E1A Sensitizes Hepatocellular Carcinoma Cells to Gemcitabine
Cancer Res., October 1, 2003; 63(19): 6229 - 6236.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. L. Cook, T. A. Miura, D. N. Ikle, A. M. Lewis Jr., and J. M. Routes
E1A Oncogene-induced Sensitization of Human Tumor Cells to Innate Immune Defenses and Chemotherapy-induced Apoptosis in Vitro and in Vivo
Cancer Res., June 15, 2003; 63(12): 3435 - 3443.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. T. Ueno, C. Bartholomeusz, W. Xia, P. Anklesaria, E. M. Bruckheimer, E. Mebel, R. Paul, S. Li, G. H. Yo, L. Huang, et al.
Systemic Gene Therapy in Human Xenograft Tumor Models by Liposomal Delivery of the E1A Gene
Cancer Res., November 15, 2002; 62(22): 6712 - 6716.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. L. Carroll, L. L. Nielsen, S. B. Pruett, and J. M. Mathis
The Role of Natural Killer Cells in Adenovirus-mediated p53 Gene Therapy
Mol. Cancer Ther., November 1, 2001; 1(1): 49 - 60.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Shao, E. M. Tsai, K. Wei, R. von Lindern, Y.-H. Chen, K. Makino, and M.-C. Hung
E1A Inhibition of Radiation-induced NF-{kappa}B Activity through Suppression of IKK Activity and I{kappa}B Degradation, Independent of Akt Activation
Cancer Res., October 1, 2001; 61(20): 7413 - 7416.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shao, R.
Right arrow Articles by Hung, M.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shao, R.
Right arrow Articles by Hung, M.-C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online